Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 10/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032816 | 0.84 | MEN1 (0.85) | BCHEMEN1KMT2AATMGAA | |
| SCHEMBL12131075 | 0.84 | MEN1 (0.85) | BCHEMEN1KMT2AATMGAA | |
| SCHEMBL2587466 | 0.83 | BCHE (1.00) | BCHEMEN1KMT2ACA12CA1 | |
| SCHEMBL3834709 | 0.82 | BCHE (0.70) | BCHEMEN1KMT2AATMGAA | |
| Hydrochloric Acid SCHEMBL4456317 | 0.81 | BCHE (0.97) | BCHEMEN1KMT2AGAAMAPT | |
| SCHEMBL6806324 | 0.81 | BCHE (0.69) | BCHEMEN1KMT2AATMGAA | |
| SCHEMBL9154589 | 0.80 | LTA4H (0.79) | BCHEMEN1KMT2AATMGAA | |
| SCHEMBL9330114 | 0.80 | MEN1 (0.69) | BCHEMEN1KMT2AATMGAA | |
| SCHEMBL3837910 | 0.80 | BCHE (0.72) | BCHEMEN1KMT2AGAAMAPT | |
| SCHEMBL3272134 | 0.80 | GAA (0.91) | BCHEMEN1KMT2AATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | BCHE 36/4885MEN1 1428/4885KMT2A 4242/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | BCHE 121/4885MEN1 1060/4885KMT2A 3426/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | BCHE 36/4885MEN1 1428/4885KMT2A 4242/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | BCHE 1481/4885MEN1 4558/4885KMT2A 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.